In the near future, clinicians should be able to use a combination of data, such as immune-PET, 18F-FDG-PET, PD-L1 IHC, TMB, tumor-infiltrating lymphocytes, and peripheral blood mononuclear cells. The gene discussed is CD274; the disease is neoplasm.